Scarlet and Sylfirm X Gain Momentum as Serendia Reaches Settlements in ITC Patent Infringement Case for the Benefit of Viol
19 Junio 2024 - 1:20AM
Business Wire
As the US International Trade Commission (USITC) prepares to
announce its final determination on July 9th, Viol’s US distributor
Serendia LLC are pleased to report significant progress in their
patent infringement litigation. Several leading medical device
companies have settled, recognizing the originality and innovation
of Viol's RF microneedling products, including Scarlet and Sylfirm
X.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240618176340/en/
Viol’s Scarlet and Sylfirm X devices
utilizing patented Na Effect technology (Photo: Viol)
Major Settlements and Ongoing Investigations
The USITC’s ongoing probe has led to settlements with major
companies accused of infringing Viol’s patents. Rohrer Aesthetics
LLC, Lutronic Corporation, SHEnB Co. LTD, Aesthetics Biomedical
Inc., and Ilooda Co. Ltd. have agreed to undisclosed settlements,
validating the strength and credibility of Viol’s patented
microneedle RF technology. Despite these significant settlements,
Jeisys Medical Inc. and EndyMed Medical Ltd. remain under
investigation. The implicated products in these infringement cases
include well-known devices such as Vivace, Virtue RF, GENIUS,
PiXel8, Secret and SecretPRO, Intensif, and Potenza.
Global Recognition of Technological Excellence
The recent settlements not only underscore the innovative nature
of Viol’s RF microneedling technology but also highlight the global
acknowledgment of Viol’s pioneering advancements. The patented "Na
Effect" technology, utilized in Scarlet and Sylfirm X, is
celebrated for its precision in delivering high-frequency energy to
the dermis, enhancing collagen production while minimizing damage
to the epidermis. This breakthrough method offers significant
clinical benefits, including reduced pain and downtime for
patients.
Market Growth and Future Potential
These settlements place Viol (KOSDAQ:335890) in a strong
position to capitalize on the rapidly growing global market for
energy-based aesthetic devices. The aging population's increasing
desire to maintain a youthful appearance has led to a surge in
non-surgical cosmetic procedures, including fat reduction, skin
tightening, and anti-aging treatments. This trend is driving
substantial growth in the market, utilizing technologies such as
lasers, radiofrequency, and ultrasound.
Technological advancements are broadening the capabilities of
energy-based aesthetic devices, enabling a wider range of safe and
effective treatments with minimal downtime and discomfort for
patients. The global market for these devices is projected to grow
at a rate of 10% per year, reaching $7.3 billion by 2025. Korean
medical device manufacturers, known for their cost efficiency and
cutting-edge technology, are well-positioned to excel in this
expanding market, making their devices highly attractive to
aesthetics practitioners worldwide.
Implications on Market Dynamics and Innovation
Viol’s successful defense of its patents and the resultant
settlements with industry giants reinforce its leadership in the
beauty medical device sector. This achievement underscores the
company’s commitment to technological advancement and the
protection of its intellectual property rights, ensuring the
continued dominance of its RF microneedling products in the
market.
Continued Innovation and Future Outlook
As Viol continues to advance its RF microneedling technology,
the recent settlements set a strong precedent for its dedication to
safeguarding intellectual property while providing cutting-edge
solutions in aesthetic dermatology. Backed by robust US patents,
Scarlet and Sylfirm X remain at the forefront of skin treatments,
offering unparalleled clinical advantages and solidifying Viol’s
status as a market leader.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240618176340/en/
Viol Co., Ltd. Carly Song +82 70-4454-5718
info@scarletrf.com